Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record.

Current Drug Targets in Obesity Pharmacotherapy – A Review

Bhat, Sangeeta P., Sharma, Arun·2017·Current Drug Targets

Abstract

Obesity, an impending global pandemic, is not being effectively controlled by current measures such as lifestyle modifications, bariatric surgery or available medications. Its toll on health and economy compels us to look for more effective measures. Fortunately, the advances in biology and molecular technology have been in our favour for delineating new pathways in the pathophysiology of obesity and have led to subsequent development of new drug targets. Development of antiobesity drugs has often been riddled with problems in the past. Some of the recently approved drugs for pharmacotherapy of obesity have been lorcaserin, phentermine/topiramate and naltrexone/ bupropion combinations. Several promising new targets are currently being evaluated, such as amylin analogues (pramlintide, davalintide), leptin analogues (metreleptin), GLP-1 analogues (exenatide, liraglutide, TTP-054), MC4R agonists (RM-493), oxyntomodulin analogues, neuropeptide Y antagonists (velneperit), cannabinoid type-1 receptor blockers (AM-6545), MetAP2 inhibitors (beloranib), lipase inhibitors (cetilistat) and anti-obesity vaccines (ghrelin, somatostatin, Ad36). Many of these groups of drugs act as "satiety signals" while others act by antagonizing orexigenic signals, increasing fat utilisation and decreasing absorption of fats. Since these targets act through various pathways, the possibility of combined use of two or more classes of these drugs unlocks numerous therapeutic avenues. Hence, the dream of personalized management of obesity might be growing closer to reality.

Overview

Integrity signals

Registry

Crossref · 10.2174/1389450118666170227153940

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 60

Metadata

Authors
Bhat, S. P., & Sharma, A.
Affiliations
Aligarh Muslim University (IN)
Corresponding author
  • Bhat, Sangeeta P.
  • Sharma, Arun
Venue
Current Drug Targets
Published
2017-05-04
Volume
18
Issue
8
Pages
983-993
ISSN
1389-4501 (ISSN-L)
OpenAlex
W2594133229
Cited by
60
References
0
Citations by year
2026: 1 · 2025: 3 · 2024: 8 · 2023: 4 · 2022: 8 · 2021: 6 · 2020: 11 · 2019: 9 · 2018: 7 · 2017: 3
FWCI
5.73
Type
journal article
Language
en
Open access
closed
Locations
  • Current Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
obesity pharmacotherapy, anti-obesity drugs, therapeutic target, lorcaserin, phentermine/topiramate, naltrexone/bupropion, amylin analogues, GLP-1 receptor agonists, MC4R agonist, MetAP2 inhibitors, lipase inhibitors, satiety signals, combination therapy
MeSH terms
Drug Therapy, Combination, Humans, Obesity, Signal Transduction, Anti-Obesity Agents, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Drug Targets in Obesity Pharmacotherapy – A Review. https://app.cochat.ai/papers/10.2174/1389450118666170227153940
The paper
Bhat, S. P., & Sharma, A. (2017). Current Drug Targets in Obesity Pharmacotherapy – A Review. Current Drug Targets. https://doi.org/10.2174/1389450118666170227153940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.